AmorChem invests in cancer immunotherapy R&D program

AmorChem, an early-stage life sciences fund managed by Canadian venture capital firm GeneChem, has entered into an agreement with Hôpital Maisonneuve-Rosemont and Univalor to participate in the financing of research at the Personalized Cancer ImmunoTherapy Program. The program, which is sponsored by Genome Canada, focuses on the development and clinical implementation of innovative personalized anti-cancer immunotherapies. The investment is AmorChem's second in the program. Earlier in 2015, the fund partnered with the University of Waterloo on a mucoadhesive nanotechnology project.